Immunogen Inc $10.78

down -0.33


31/7/2014 04:00 PM  |  NASDAQ : IMGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get IMGN Trend Analysis - it has underperformed the S&P 500 by 58%

Partner Headlines

  1. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus
  2. Wednesday's Biggest Movers

    Benzinga
  3. Shares Of ImmunoGen Down On Morgan Stanley's Bearish Initiation

    Benzinga
  4. Benzinga's Top Initiations

    Benzinga
  5. UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase ...

    Benzinga
  6. ImmunoGen Says Initial Research Shows New Dosing Approach for IMGN853 Achieves ...

    Benzinga
  7. IDEXX Laboratories Elects Daniel Junius to Board of Directors

    Benzinga
  8. US Stock Futures Down Ahead Of Wal-Mart Earnings, Economic Data

    Benzinga
  9. CytomX Therapeutics, ImmunoGen Announce Strategic Collaboration

    Benzinga
  10. ImmunoGen Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat ...

    Benzinga
  11. US Stock Futures Edge Lower Ahead Of FOMC Minutes, Economic Data

    Benzinga
  12. ImmunoGen Announces Approval of Roche's Kadcyla in EU

    Benzinga
  13. UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of ...

    Benzinga
  14. Benzinga's Top #PreMarket Losers

    Benzinga
  15. ImmunoGen Announces License Agreement with Novartis

    Benzinga
  16. Mid-Afternoon Market Update: Marvell Rises on KKR Stake While Orbitz Gives ...

    Benzinga
  17. Mid-Day Market Update: BroadSoft Drops On Q3 Results; Endo Health Shares ...

    Benzinga
  18. Mid-Morning Market Update: Markets Open Lower; CVS Caremark Lifts Outlook

    Benzinga
  19. Benzinga's Top #PreMarket Losers

    Benzinga
  20. US Stock Futures Signal Lower Start On Wall Street

    Benzinga
  21. ImmunoGen Presents SAR566658 Clinical Findings at AACR-NCI-EORTC Conference ...

    Benzinga
  22. US Stock Futures Up; J.P. Morgan Earnings In Focus

    Benzinga
  23. ImmunoGen Announces New License Agreement with Novartis

    Benzinga
  24. ImmunoGen Announces Positive Results from Kadcyla Phase III Trial, TH3RESA ...

    Benzinga
  25. The 'L' In CANSLIM Stands For Leaders, Not Laggards

    IBD
  26. UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

    Benzinga
  27. Earnings Scheduled For January 25, 2013

    Benzinga
  28. From Earlier: Amgen Takes Third License for Rights to Use ImmunoGen's TAP ...

    Benzinga
  29. ImmunoGen Clinical Results of IMGN901

    Benzinga
  30. A Peek Into the Market Before the Trading Begins

    Benzinga
  31. ImmunoGen Announces Dr. Charles Morris as New Chief Development Officer

    Benzinga
  32. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus
  33. It's All Bad News For ImmunoGen After 1Q13 Earnings Release

    Benzinga
  34. Health Care Sector Wrap

    FoxBusiness
  35. Benzinga's Top Pre-Market Gainers

    Benzinga
  36. A Peek Into The Market Before The Trading Starts

    Benzinga
  37. ImmunoGen

    IBD
  38. Health Care Sector Wrap

    FoxBusiness
  39. UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on ImmunoGen

    Benzinga
  40. Infosys Ltd ADR, Kroger Among Stocks Down on High Volume Thursday

    FoxBusiness
  41. Benzinga's Top Pre-Market Losers

    Benzinga
  42. ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and ...

    Benzinga
  43. Benzinga's Initiation Summary for June 14, 2012

    Benzinga
  44. UPDATE: Cantor Fitzgerald Initiates Hold, $15 PT on ImmmunoGen; In Need ...

    Benzinga
  45. From Earlier: ImmunoGen Announces Development of Trastuzumab Emtansine ...

    Benzinga
  46. From Earlier: ImmunoGen Announces Results from Trastuzumab Emtansine (T-DM1) ...

    Benzinga
  47. Stocks Set to Close Quarter on High Note with Finish Line (FINL) and Research ...

    MarketIntelligenceCenter
  48. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus
  49. ImmunoGen Up 7% After Earnings Beat

    Benzinga
  50. ImmunoGen

    IBD
Trading Center